This document is a regulatory filing from Dr. Reddy's Laboratories Ltd. to the BSE Surveillance department. It is a response to an email query from the stock exchange dated September 17, 2026, which sought clarification on a news article published on the Economic Times Pharma platform on the same date.
The news article in question was captioned "Dr Reddy's gets voluntary license for Gilead's once-yearly HIV prevention drug".
The company confirms that the news item is correct and pertains to a press release it issued on September 17, 2026, titled "Dr. Reddy's expands collaboration with Gilead Sciences through voluntary licensing agreement for investigational once-yearly lenacapavir for HIV prevention."
In response to specific queries from the exchange:
- The company stated that providing a sequence of negotiations was "Not Applicable".
- The company stated that at this stage, there is no other undisclosed material information that could explain any movement in trading.
- The company stated that questions regarding regulatory/legal proceedings were "Not Applicable".
Crucially, the company explicitly states that this matter does not constitute a material event or information requiring disclosure under Regulation 30 of the SEBI Listing Regulations. The company affirms its policy of making timely disclosures of all events considered material under the regulations.
The letter is signed by K Randhir Singh, the Company Secretary, Compliance Officer and Head-CSR, and is digitally dated September 18, 2026, at 08:32:45 IST.